Please provide your email address to receive an email when new articles are posted on . The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be ...
Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...
Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...
Credit: Fresenius Kabi. Tyenne is indicated for treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, active polyarticular juvenile idiopathic arthritis, and active ...
Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved tocilizumab ...
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...
Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data indicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results